Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Sema4 reports advances re oncology, COVID-19

Sema4 has ramped up the capacity for its coronavirus testing program to about 15,000 tests daily, an initiative praised by elected officials including U.S. Sen. Chris...

| By Kelley Gipson

Boehringer creates Shanghai hub re Chinese R&D

Boehringer Ingelheim has opened a site in Shanghai to connect its R&D, business development and venture capital groups to Chinese drug developers. The site brings...

| By Kelley Gipson

UConn-designed COVID-19 mask coming to market

Within six weeks of announcing a successful method to fabricate custom-fit mask frames to optimize protection from the spread of COVID-19, UConn has a licensing...

| By Kelley Gipson

Branford’s Tangen wins NY contract re superbug

Branford diagnostics company Tangen Biosciences has won a contract from New York state’s health department to develop a point-of-care device to detect Candida auris, a...

| By Kelley Gipson

Bloomberg innovation survey again ranks CT high

Connecticut continues to punch above its weight in Bloomberg’s ranking of the most innovative U.S. states, placing fourth for the second year in a row....

| By Kelley Gipson

Pfizer sees positive results re COVID-19 vaccine

Pfizer and their partners at the mRNA specialist BioNTech have published the first glimpse of biomarker data from an early-stage study spotlighting the “robust immunogenicity”...

| By Kelley Gipson

Bioasis and Chiesi announce licensing agreement

Bioasis Technologies and Chiesi Global Rare Diseases have entered into a worldwide, exclusive licensing agreement re the Bioasis platform technology, with a focus on four...

| By Kelley Gipson

Alexion reports progress re ULTOMIRIS®

Alexion Pharmaceuticals reports that the European Commission has approved ULTOMIRIS® (ravulizumab) — for certain adults and children with atypical hemolytic uremic syndrome (aHUS) … more Separately, Alexion...

| By Kelley Gipson

BioCT welcomes Erika Smith to Board

BioCT is pleased to welcome Erika Smith to the Board of Directors. Erika is the CEO of ReNetX Bio, a clinical stage, venture funded company in...

| By Kelley Gipson

NCI renews JAX cancer center designation

The Jackson Laboratory (JAX) reports that the National Cancer Institute has renewed JAX’s prestigious Cancer Center Support Grant for the 34th year. As one of...